This page provides comprehensive information about the topic.
Senolytic drugs selectively eliminate senescent cells that accumulate with aging and contribute to neurodegeneration through the senescence-associated secretory phenotype (SASP).
The study of Senolytic Drugs For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Senescent cells accumulate in the aging brain through multiple mechanisms including telomere shortening, DNA damage accumulation, and mitochondrial dysfunction. These cells enter a permanent cell cycle arrest characterized by upregulated cell cycle inhibitors p16^INK4a and p21CIP1. The senescent state is maintained by epigenetic changes that lock cells into this arrested condition, making them resistant to apoptotic signals.
Different senolytic agents work through distinct molecular pathways to eliminate senescent cells. Dasatinib inhibits multiple tyrosine kinases including DDR1 and DDR2, which are involved in senescent cell survival signaling. Quercetin is a broad-spectrum inhibitor that targets multiple pro-survival pathways including PI3K, AKT, and mTOR. The combination is synergistic because senescent cells rely on multiple survival pathways.
Navitoclax and other Bcl-2 family inhibitors target the anti-apoptotic proteins Bcl-2, Bcl-xL, and Bcl-w that are upregulated in senescent cells. These proteins prevent mitochondrial outer membrane permeabilization and caspase activation. By blocking their function, these agents restore the apoptotic pathway in senescent cells.
Several clinical trials are evaluating senolytics in Alzheimer's disease. The Mayo Clinic has conducted trials with dasatinib plus quercetin (NCT04063124) and fisetin (NCT03675724) in early AD patients. Primary outcomes include safety, tolerability, and markers of senescent cell burden. Biomarker endpoints include CSF inflammatory markers and neuroimaging measures of brain atrophy.
Pilot studies in Parkinson's disease have evaluated senolytic treatment in patients with progressive supranuclear palsy, a related neurodegenerative disorder (NCT03770494). These studies examine whether removing senescent cells can slow disease progression. Measures of motor function and cognitive performance are tracked.
Senolytic treatment is associated with transient side effects including thrombocytopenia (with Bcl-2 inhibitors), fluid retention, and gastrointestinal symptoms. Because senolytic agents temporarily reduce the senescence burden rather than permanently eliminating senescent cells, repeated dosing may be required. The optimal dosing schedule for neurodegenerative diseases remains under investigation.
Cell cycle inhibitors p16^INK4a and p21CIP1 are established markers of cellular senescence. p16^INK4a expression can be measured in peripheral blood mononuclear cells as a proxy for systemic senescence burden. Higher p16^INK4a levels correlate with chronological age and have been associated with poorer outcomes in neurodegenerative diseases.
Circulating SASP components including IL-6, IL-8, and growth differentiation factor 15 (GDF15) can serve as biomarkers of senescence. Elevated levels of these inflammatory mediators have been reported in Alzheimer's and Parkinson's disease patients. Changes in SASP factor levels following senolytic treatment may indicate biological activity.
PET ligands that bind to senescent cell-associated antigens are under development. These molecular imaging probes could allow visualization of senescence burden in the living brain and monitoring of treatment response.
Preclinical studies suggest that sequential treatment with different senolytic agents may improve efficacy. A first agent eliminates a subset of senescent cells, after which a second agent targets a different population. This approach may achieve more complete senescence clearance than single-agent treatment.
Senostatic drugs suppress the SASP without eliminating senescent cells, offering an alternative approach. Rapamycin and other mTOR inhibitors reduce SASP production while allowing senescent cells to persist. Combining senolytic and senostatic approaches may provide complementary benefits.
Senolytic treatment may enhance the efficacy of other neurodegenerative disease therapies. By reducing chronic inflammation, senolytics could improve drug delivery across the blood-brain barrier and enhance neuronal function. Combination approaches with disease-modifying therapies are planned for future clinical trials.